Developing a biological age assessment equation using principal component analysis and clinical biomarkers of aging in Korean men

The purpose of the present study is to find clinically useful candidate biomarkers of aging,and using these to develop an equation measuring biological age(BA) in Korean men, then to validate the clinical usefulness of it. Among 4288 men who received medical health examinations, we selected 1588 men who met the normality criteria of each variable. We assumed that chronological ages (CA) of healthy persons represent the BA of them. Variables showing significant correlations with CA were selected. Redundant variables were excluded. We selected 11 variables: VO(2)max, percent body fat (%BF), waist circumference (WC), forced expiratory volume in 1s (FEV1), systolic blood pressure (SBP), low density cholesterol (LDLCH), blood urea nitrogen (BUN), serum albumin (SA), erythrocyte sedimentation rate(ESR) hearing threshold (HT), and glycosylated hemoglobin (HBA1C). These 11 variables were then submitted into principal component analysis (PCA) and standardized BA scores were obtained. Using them and T-scale idea, the following equation to assess BA was developed: BA= -28.7+0.83(%BF)+0.48(WC)+0.13(SBP)- 0.27(VO(2)max)+ 0.19(HT)-3.1(FEV1)+0.32(BUN)+0.06(LDLCH)-3.0(SA)+0.34(ESR)+ 4.6(HBA1C). We compared the BA of 3122 men by their fasting glucose and age level. The BA of the higher glucose level group was significantly higher than that of others at all CA levels. the selected 11 biomarkers encompassed known clinically important factors of adult diseases and functional disabilities. This BA assessment equation can be used in the general Korean male Population and it proved to be clinically useful. (C) 2008 Elsevier Ireland Ltd. All rights reserved.NAKAMURA E, 1994, EXP GERONTOL, V29, P151COOK NR, 1991, AM J EPIDEMIOL, V133, P784GATES GA, 1990, EAR HEARING, V11, P247LIGTHART GJ, 1990, MECH AGEING DEV, V55, P89FOZARD JL, 1990, J GERONTOL, V45, P116HOCHSCHILD R, 1990, J GERONTOL, V45, P187HOCHSCHILD R, 1989, EXP GERONTOL, V24, P289NAKAMURA E, 1988, MECH AGEING DEV, V46, P1FLEG JL, 1988, J APPL PHYSIOL, V65, P1147BURT VL, 1995, HYPERTENSION, V25, P305McClearn GE, 1997, EXP GERONTOL, V32, P87Nakamura E, 1998, EXP GERONTOL, V33, P421KRUTKO VN, 2001, FIZIOL CHELOVEKA, V27, P88KRUTKO VN, 2002, FIZIOL CHELOVEKA, V28, P95ERLICHMAN J, 2002, OBES REV, V3, P257UENO LM, 2003, J PHYSL ANTHR APPL H, V22, P37Andresdottir MB, 2003, AM J EPIDEMIOL, V158, P844, DOI 10.1093/aje/kwg222Shaper AG, 2004, J CLIN EPIDEMIOL, V57, P195, DOI 10.1016/j.jclinepi.2003.07.001Stone NJ, 2005, AM J CARDIOL, V96, p53E, DOI 10.1016/j.amjcard.2005.06.006*ADA, 2007, DIABETES CARE S, V1, pS4Zhang XL, 2007, ARCH INTERN MED, V167, P886, DOI 10.1001/archinte.167.9.886BAKER GT, 1988, EXP GERONTOL, V23, P223DUBINA TL, 1984, EXP GERONTOL, V19, P133VOITENKO VP, 1983, EXP AGING RES, V9, P239DUBINA TL, 1983, EXP GERONTOL, V18, P5INGRAM DK, 1983, EXP AGING RES, V9, P225HOFECKER G, 1980, MECH AGEING DEV, V14, P345LUDWIG FC, 1980, EXP AGING RES, V6, P497WEBSTER IW, 1976, J GERONTOL, V31, P546FURUKAWA T, 1975, J GERONTOL, V30, P422HEIKKINE.E, 1974, GERONTOLOGY, V20, P33FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499